Brokers Offer Predictions for Legend Biotech FY2025 Earnings

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Legend Biotech in a research note issued to investors on Thursday, January 22nd. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.32) per share for the year, up from their prior forecast of ($1.34). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Legend Biotech had a negative return on equity of 24.47% and a negative net margin of 26.37%.The company had revenue of $272.33 million for the quarter, compared to the consensus estimate of $277.91 million. During the same period last year, the business posted ($0.34) earnings per share. The firm’s revenue was up 70.0% compared to the same quarter last year.

LEGN has been the subject of several other reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $66.00 price objective on shares of Legend Biotech in a research report on Tuesday, January 20th. UBS Group reduced their price target on shares of Legend Biotech from $54.00 to $48.00 and set a “buy” rating for the company in a report on Monday, December 8th. TD Cowen restated a “hold” rating and issued a $21.00 price target (down from $62.00) on shares of Legend Biotech in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Legend Biotech in a report on Monday, December 29th. Finally, Johnson Rice set a $60.00 target price on shares of Legend Biotech in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Legend Biotech presently has an average rating of “Moderate Buy” and an average price target of $58.50.

Legend Biotech Stock Performance

LEGN opened at $18.96 on Monday. The company has a quick ratio of 2.80, a current ratio of 2.86 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average price is $23.71 and its two-hundred day moving average price is $31.07. The firm has a market capitalization of $3.50 billion, a P/E ratio of -29.17 and a beta of 0.12. Legend Biotech has a 12-month low of $18.76 and a 12-month high of $45.30.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Matthews International Capital Management LLC boosted its holdings in Legend Biotech by 17.3% during the second quarter. Matthews International Capital Management LLC now owns 1,293,052 shares of the company’s stock valued at $45,890,000 after purchasing an additional 191,165 shares in the last quarter. Vontobel Holding Ltd. bought a new position in shares of Legend Biotech during the 2nd quarter worth approximately $382,000. Vanguard Personalized Indexing Management LLC bought a new stake in Legend Biotech in the second quarter valued at $219,000. TD Asset Management Inc grew its position in Legend Biotech by 9.8% in the second quarter. TD Asset Management Inc now owns 103,392 shares of the company’s stock valued at $3,669,000 after acquiring an additional 9,200 shares during the period. Finally, Allianz Asset Management GmbH acquired a new position in Legend Biotech during the second quarter worth $458,000. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.